Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lymphoma, T-Cell, Peripheral 7Multiple Myeloma 4Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1

Interventions

Temozolomide 4Erlotinib Hydrochloride 4Bevacizumab 4temsirolimus 3Radiotherapy 3Carboplatin 3etoposide phosphate 2Sirolimus 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Cetuximab 2Carmustine 2veliparib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sodium thiosulfate 1romidepsin 1picropodophyllin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1mirdametinib 1irofulven 1efaproxiral 1carotuximab 1cabazitaxel 1acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Spinal Puncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oligodendroglioma × romidepsin × Clear all
NCT00085540 2017-01-02

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
50 enrolled 6 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡